These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

44 related articles for article (PubMed ID: 230552)

  • 1. (3,4-Dihydroxybenzyl)-2-imidazoline (DHBI): an analogue of dopamine.
    O'Donnell JP; Azzaro AJ; Urquilla PR
    Res Commun Chem Pathol Pharmacol; 1979 Nov; 26(2):243-51. PubMed ID: 230552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of dopamine receptors mediating inhibition of adenylate cyclase activity in rat striatum.
    Onali P; Olianas MC; Gessa GL
    Mol Pharmacol; 1985 Aug; 28(2):138-45. PubMed ID: 2410769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies on vascular dopamine receptors with the dopamine receptor agonist: SK&F 82526.
    Ohlstein EH; Zabko-Potapovich B; Berkowitz BA
    J Pharmacol Exp Ther; 1984 May; 229(2):433-9. PubMed ID: 6143817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. M-1 and M-2 muscarinic receptor-mediated inhibition of dopamine-sensitive adenylate cyclase in rat neostriatum: a permissive role for D-2 dopamine receptors.
    Schoffelmeer AN; Hogenboom F; Mulder AH
    J Pharmacol Exp Ther; 1988 May; 245(2):658-63. PubMed ID: 2452877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopamine, acting through D-2 receptors, inhibits rat striatal adenylate cyclase by a GTP-dependent process.
    Cooper DM; Bier-Laning CM; Halford MK; Ahlijanian MK; Zahniser NR
    Mol Pharmacol; 1986 Feb; 29(2):113-9. PubMed ID: 3005824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic sulpiride treatment produces supersensitivity of striatal adenylate cyclase to dopamine in sexually immature or adult castrated rats.
    Gnegy ME; Bernabei A; Treisman G
    J Pharmacol Exp Ther; 1983 Mar; 224(3):627-33. PubMed ID: 6827485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Action of etmozin and ethacizin on dopaminergic adenylate cyclase of the striate system of the brain].
    Baldenkov GN; Ratner EI; Rozenshtraukh LV; Tkachuk VA
    Biull Eksp Biol Med; 1984 Oct; 98(10):448-50. PubMed ID: 6149776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mu- and delta-opioid receptor-mediated inhibition of adenylate cyclase activity stimulated by released endogenous dopamine in rat neostriatal slices; demonstration of potent delta-agonist activity of bremazocine.
    Heijna MH; Hogenboom F; Portoghese PS; Mulder AH; Schoffelmeer AN
    J Pharmacol Exp Ther; 1989 Jun; 249(3):864-8. PubMed ID: 2543814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective influence of ergot alkaloids on cortical and striatal dopaminergic and sergotonergic receptors.
    Rosenfeld MR; Makman MH; Ahn HS; Thal LJ; Mishra RK; Katzman R
    Adv Biochem Psychopharmacol; 1980; 23():83-93. PubMed ID: 6249092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Similarities and differences of dopamine receptors in the renal vascular bed and elsewhere.
    Goldberg LI; Volkman PH; Kohli JD; Kotake AN
    Adv Biochem Psychopharmacol; 1977; 16():251-6. PubMed ID: 196488
    [No Abstract]   [Full Text] [Related]  

  • 11. Dopamine-sensitive adenylate-cyclase in rabbit superior mesenteric artery.
    Collier WL; De Rossi M; Amenta F
    Arch Int Pharmacodyn Ther; 1984 Mar; 268(1):106-12. PubMed ID: 6329113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of chronic SCH23390 treatment on the biochemical and behavioral properties of D1 and D2 dopamine receptors: potentiated behavioral responses to a D2 dopamine agonist after selective D1 dopamine receptor upregulation.
    Hess EJ; Albers LJ; Le H; Creese I
    J Pharmacol Exp Ther; 1986 Sep; 238(3):846-54. PubMed ID: 3018223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of two manifestations of dopamine receptor supersensitivity by administration of L-dopa.
    Friedhoff AJ; Bonnet K; Tosengarten H
    Res Commun Chem Pathol Pharmacol; 1977 Mar; 16(3):411-23. PubMed ID: 847296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the effects of dopamine1- and dopamine2-receptor agonists on the cAMP generating system in canine coronary and renal arteries.
    Wang WZ; Zhao RR; Qin FZ
    Methods Find Exp Clin Pharmacol; 1994 Dec; 16(10):691-6. PubMed ID: 7723468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of clozapine on rat striatal muscarinic receptors coupled to inhibition of adenylyl cyclase activity and on the human cloned m4 receptor.
    Olianas MC; Maullu C; Onali P
    Br J Pharmacol; 1997 Oct; 122(3):401-8. PubMed ID: 9351494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the effects of dopamine and beta-adrenergic agonists on adenylate cyclase of renal glomeruli and striatum.
    Kotake C; Hoffmann PC; Goldberg LI; Cannon JG
    Mol Pharmacol; 1981 Sep; 20(2):429-34. PubMed ID: 6117789
    [No Abstract]   [Full Text] [Related]  

  • 17. Acute in vivo amphetamine produces a homologous desensitization of dopamine receptor-coupled adenylate cyclase activities and decreases agonist binding to the D1 site.
    Roseboom PH; Gnegy ME
    Mol Pharmacol; 1989 Jan; 35(1):139-47. PubMed ID: 2563306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of dopaminergic ergot derivatives with cyclic nucleotide system.
    Spano PF; Saiani L; Memo M; Trabucchi M
    Adv Biochem Psychopharmacol; 1980; 23():95-102. PubMed ID: 6249093
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of isoprenaline on dopamine receptors in the rabbit isolated renal artery.
    Kelly MJ
    Experientia; 1981; 37(8):889-90. PubMed ID: 6269874
    [No Abstract]   [Full Text] [Related]  

  • 20. Preparation and biological actions of N-2,2,2-trifluoroethyl-2-(3,4-dihydroxyphenyl)ethylamine.
    O'Donnell JP; Azzaro AJ; Urquilla PR
    J Pharm Sci; 1980 Feb; 69(2):149-52. PubMed ID: 7359313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.